Base Therapeutics, a Guangdong-based firm specializing in base editing and prime editing technologies, has reportedly raised “tens of millions” of US dollars in a Series A1 financing round. The funding was led by Great Eagle VC, with participation from Baidu Venture, Sincere Capital, GDHT Capital, SPARK VC, and existing investor Highlight Capital. The proceeds will be used to advance multiple base editing pipelines into the Investigational New Drug (IND) filing and clinical trial stages.
Platform and Pipeline Development
Founded in 2021, Base Therapeutics has quickly established itself as a leader in the gene editing space, boasting a portfolio of nearly 200 base editing tools. The company’s core product features “zero off-target” effects, high targeting editing efficiency, and a small size, making it highly suitable for therapeutic applications. Base Therapeutics is currently developing off-the-shelf natural killer (NK) cell therapies and in vivo gene editing therapies, while also optimizing and developing new gene editing technologies.
Market and Future Outlook
The successful completion of the Series A1 financing round underscores Base Therapeutics’ potential to drive innovation in gene editing and gene therapy. With strong financial backing and a robust pipeline, the company is well-positioned to advance its base editing programs towards clinical validation. The development of off-the-shelf NK cell therapies and in vivo gene editing treatments could address significant unmet needs in the field of genetic medicine, positioning Base Therapeutics as a key player in the global gene editing market.-Fineline Info & Tech
